Innovation is not Optional. Are you ready?

Dr. Haders has 20+ years of experience in healthcare as a scientist, entrepreneur, advisor & investor. Dr. Haders is currently the Co-Founder and CEO of Model Medicines, a PIND stage AI/ML Drug Discovery company that has built a pipeline of novel acting broad-spectrum antiviral, oncology and GI assets (https://www.modelmedicines.com/pipeline), including the potential best-in-class, first-in-class MDL-001. More information about MDL-001 and the oncology program can be found here (https://www.modelmedicines.com/newsroom). Model Medicines has raised over $8M to date with backing from investors including 8VC, Friedman Bioventures, Irving Ventures and ParticleX. Prior to co-founding Model Medicines, Daniel launched the Nex Cubed Digital Health Accelerator. Here, Daniel built an early-stage investment portfolio of 25+ Digital Healthcare companies with an enterprise value of over $250M, investment results that would place the portfolio in the top decile. The accelerator has been named one of the Top Ten Global Digital Health Accelerators and The Best Accelerators & Incubators for FemTech Startups. He is also an Operating Partner at Sway Ventures, leading Digital Health investing and portfolio oversight. Dr. Haders is a Board Observer at AppliedVR, a VR digital therapeutic company, backed by investors including F-Prime, Jazz, SVB, JJDC and Sway, which was granted break though device designation and cleared by the FDA in 2022. Other investments include MedCrypt, which recently closed its Series B with co-investors including Dexcom, JJDC, Intuitive Ventures, and Section 32 among others. Dr. Haders is a Faculty Member and Member of the Advisory Committee of the UCSD, Digital Health Certificate Program and a Member of the BioMedX Oversight Committee at Columbia University Technology Ventures. Prior to his current roles, Dr. Haders held positions from research fellow to senior scientist to Co-Founder/CEO in the fields of medical devices, pharmaceuticals & nano-drug delivery. At LuxBio, Daniel and Model Medicines Co-Founder Sean Russell helped develop LX214 from concept through a successful Phase I study. The LX214 program/formulation was further developed clinically by Sun Pharma & gained FDA approval under the name CEQUA in 2018. Dr. Haders holds both a BS and PhD in Biomedical Engineering and has been awarded multiple Fellowships for scientific research including a National Science Foundation IGERT Fellowship in Integratively Engineered Biointerfaces and a Department of Education GAANN Fellowship in Molecular, Cellular and Nanosystems Bioengineering.

Ms. Longmore-Grund is a global "C" level executive with deep strategic, operational and financial leadership experience across a variety of company profiles ranging from public and private Fortune 100, mid cap, PE and venture-funded startups. She has significant capital markets experience, leading 30+ transformational M&A and capital formation transactions with ~ $3.5B of value and building high performing leadership teams who successfully deliver sustainable growth and shareholder value. Ms. Longmore-Grund served as President, Chief Executive Officer and Director of Alliance HealthCare Services from 2018 to 2021. When Alliance was acquired in September of 2021 by Akumin Inc. (NASDAQ: AKU), Ms. Longmore-Grund served as President and Co-CEO as well as Director of the newly merged Akumin company to facilitate a smooth transition and integration through March of 2022. With the acquisition of Alliance HealthCare Services, Akumin became the leading provider of comprehensive radiology and oncology healthcare services, operating ~200 fixed site outpatient imaging and radiation therapy centers, providing outsourced services to over 1,000 hospital partners and locations across 46 states and caring for approximately 2M patients per year. Prior to serving as CEO, Ms. Longmore-Grund served in a variety of financial executive roles. She served as Executive Vice President & Chief Financial Officer of Alliance HealthCare Services (NASDAQ: AIQ), Senior Vice President and Chief Financial Officer for Printronix, a global provider of industrial print technology solutions serving Fortune 500 customers across 100 countries in mission critical manufacturing and supply chain applications. She has also served as the Chief Financial Officer of Velocium, now a Northrop Grumman company.

Omid Toloui is the Vice President of Innovation at Elevance Health, where his team reinvents healthcare by identifying, incubating, and implementing innovative solutions to today’s most urgent challenges. Under Omid’s leadership the team has become a catalyst for impact, partnering with business and technology leaders and visionary startups to help Elevance Health improve the health of the more than 119 million people it serves. Prior to his current role, Omid was the Vice President of Digital Health at CareMore & Aspire Health, a subsidiary of Elevance Health focused on innovative care delivery. Omid earned his Master of Business Administration, Master of Public Health in Health Services Management, and Bachelor of Science in Psychobiology from UCLA, where he is also on the faculty of the UCLA Anderson School of Management.

Tim has a diverse and proven track record of success as an entrepreneur, corporate executive, private equity investor and strategy consultant. Tim is a mission-driven leader with an ability to build, inspire and lead high performing teams. Tim is currently the SVP, Global Head of Commercialization for Roche Information Solutions. In that capacity he leads the end-to-end commercialization of a digital health portfolio which includes workflow, analytics, clinical decision support solutions across oncology, cardiometabolic and neurodegenerative disease areas. Prior to Roche, Tim was a co-founder and Chief Commercial Officer at Viewics, which was acquired by Roche in 2017. Viewics was a healthcare analytics platform which became a market leader in clinical and operational analytics for laboratories. Prior to Viewics, Tim was a founding member of the Applied Technology Investing Team at Opus Capital. He began his career at Stockamp & Associates (Acquired by Huron) leading revenue cycle and patient progression projects at leading academic medical centers and health systems across the U.S. Tim holds a bachelor of Management Science, with honors, from the University of California, San Diego and an MBA from the University of California Haas School of Business with a focus on healthcare.